Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma

The current study aimed to evaluate the efficacy and safety of neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S-1) plus oxaliplatin (SOX) chemotherapy in patients with locally advanced gastric carcinoma (LAGC). Therefore, patients with LAGC treated with neoadjuvant apatinib plus SOX...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhenfeng, He, Tingbang, Yu, Deguo, Qin, Xiantao, Geng, Aizhi, Yang, Hailei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468841/
https://www.ncbi.nlm.nih.gov/pubmed/36160880
http://dx.doi.org/10.3892/etm.2022.11562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468841/
https://www.ncbi.nlm.nih.gov/pubmed/36160880
http://dx.doi.org/10.3892/etm.2022.11562

Ejemplares similares